Top

Published in:

01-09-2010 | Original Article

Production of monoclonal antibodies to P-glycoprotein: its application in detection of soluble and surface P-glycoprotein of leukemia patients

Authors: Sawitree Chiampanichayakul, Songyot Anuchapreeda, Nuttapol Chruewkamlow, Kodchakorn Mahasongkram, Pattra Thanaratanakorn, Watchara Kasinrerk

Published in: International Journal of Hematology | Issue 2/2010

Abstract

Multidrug resistance (MDR) in leukemia is commonly associated with the expression of a transmembrane protein, P-glycoprotein (P-gp). In this study, two monoclonal antibodies (mAbs) specific for the extracellular domain of P-gp were generated. By employing the generated mAbs, a two-color lysed whole blood flow cytometric method for surface P-gp and an efficient sandwich ELISA for soluble P-gp determinations were established. By using the established methods, surface and soluble P-gp were detected in several leukemia patients. The presence of soluble P-gp could be used to identify the P-gp surface expression patients. Detection of soluble P-gp reported provides a new basis that may lead to a better understanding of the MDR mechanism in leukemia.

Roninson IB, editor. Molecular and cellular biology of multidrug resistance in tumour cells. New York: Plenum Press; 1990.

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–98.CrossRefPubMed

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.CrossRefPubMed

Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 1994;13:223–33.CrossRefPubMed

Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989;81:116–24.CrossRefPubMed

Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316:820–3.CrossRefPubMed

Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988;48:1926–9.PubMed

Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA. 1992;89:5824–8.CrossRefPubMed

Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res. 1992;52:1810–6.PubMed

10.

Arceci RJ, Stieglitz K, Bras J, Schinkel A, Baas F, Croop J. Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res. 1993;53:310–7.PubMed

11.

Chu TM, Kawinski E, Lin TH. Characterization of a new monoclonal antibody F4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines. Hybridoma. 1993;12:417–29.CrossRefPubMed

12.

Cianfriglia M, Romagnoli G, Tombesi M, Poloni F, Falasca G, Di Modugno F, et al. P-glycoprotein epitope mapping. II. The murine monoclonal antibody MM6.15 to human multidrug-resistant cells binds with three distinct loops in the MDR1-P-glycoprotein extracellular domain. Int J Cancer. 1995;61:142–7.CrossRefPubMed

13.

Krishan A, Sauerteig A, Stein JH. Comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells. Cytometry. 1991;12:731–42.CrossRefPubMed

14.

Chu TM, Lin TH, Kawinski E. Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem Biophys Res Commun. 1994;203:506–12.CrossRefPubMed

15.

Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998;4:389–98.PubMed

16.

Kerboeuf D, Gueqnard F, Vern YL. Detection of P-glycoprotein-mediated multidrug resistance against anthelmintics in haemonchus contortus using anti-human mdr1 monoclonal antibodies. Parasitol Res. 2003;91:79–85.CrossRefPubMed

17.

Chen BA, Du J, Zhang CX, Cheng J, Gao F, Lu ZH. Detection of multidrug-resistance proteins with protein array chips. Zhonghua Zhong Liu Za Zhi. 2005;27:528–30.PubMed

18.

Jakab K, Gopcsa L, Adam E, Domian G, Sarkadi B, Paloczi K. Application of flow cytometry immunophenotyping and multidrug resistance assay in B-cell acute lymphoid leukemia and multiple myeloma. Neoplasma. 2005;52:36–42.PubMed

19.

Kasinrerk W, Tokrasinwit N, Phunpae P. CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway. Immunology. 1999;96:184–92.CrossRefPubMed

20.

Tayapiwatana C, Kuntaruk S, Tatu T, Chiampanichayakul S, Munkongdee T, Winichagoon P, Fuchareon S, Kasinrerk W. Simple method for screening of alpha-thalassaemia 1 carriers. Int J Hematol. 2009;89:559–67.CrossRefPubMed

21.

Nouanthong P, Pata S, Sirisanthana T, Kasinrerk W. A simple manual rosetting method for absolute CD4+ lymphocyte counting in resource-limited countries. Clin Vaccine Immunol. 2006;13:598–601.CrossRefPubMed

22.

Kuntaruk S, Tatu T, Keowkarnkah T, Kasinrerk W. Sandwich ELISA for hemoglobin A(2) quantification and identification of beta-thalassemia carriers. Int J Hematol. 2010;91:219–28.CrossRefPubMed

23.

Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427.CrossRefPubMed

24.

Fisher GA, Sikic BI. Drug resistance in clinical oncology and hematology. Introduction. Hematol Oncol Clin N Am. 1995;9(2):xi–xii.

25.

Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer A. 1996;32(6):912–20.CrossRef

Title: Production of monoclonal antibodies to P-glycoprotein: its application in detection of soluble and surface P-glycoprotein of leukemia patients
Authors: Sawitree Chiampanichayakul
Songyot Anuchapreeda
Nuttapol Chruewkamlow
Kodchakorn Mahasongkram
Pattra Thanaratanakorn
Watchara Kasinrerk
Publication date: 01-09-2010
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 2/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0668-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor

Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities

Comorbidities in patients with persistent or chronic immune thrombocytopenia

IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia

Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma

The association of protein S Tokushima-K196E with a risk of deep vein thrombosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer